Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function
SA Long, M Rieck, S Sanda, JB Bollyky, PL Samuels… - Diabetes, 2012 - Am Diabetes Assoc
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats
autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and …
autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and …
Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells
M Battaglia, A Stabilini, E Draghici, B Migliavacca… - Diabetes, 2006 - Am Diabetes Assoc
Success in developing novel therapies to recommence self-tolerance in autoimmunity
depends on the induction of T regulatory (Tr) cells. Here, we report that rapamycin combined …
depends on the induction of T regulatory (Tr) cells. Here, we report that rapamycin combined …
Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4+CD25+FOXP3+ Regulatory T-Cells
P Monti, M Scirpoli, P Maffi, L Piemonti, A Secchi… - Diabetes, 2008 - Am Diabetes Assoc
OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft
rejection in humans, which is considered permissive for tolerance induction. Rapamycin …
rejection in humans, which is considered permissive for tolerance induction. Rapamycin …
Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice
WL Baeder, J Sredy, SN Sehgal… - Clinical & …, 1992 - Wiley Online Library
The effect of the immunosuppressive agent rapamycin (RAPA) was assessed in the non‐
obese diabetic (NOD) mouse which is an autoimmune model of IDDM. RAPA was prepared …
obese diabetic (NOD) mouse which is an autoimmune model of IDDM. RAPA was prepared …
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice
A Rabinovitch, WL Suarez-Pinzon, AMJ Shapiro… - Diabetes, 2002 - Am Diabetes Assoc
Sirolimus is an immunosuppressant that inhibits interleukin (IL)-2 signaling of T-cell
proliferation but not IL-2-induced T-cell apoptosis. Therefore, we hypothesized that …
proliferation but not IL-2-induced T-cell apoptosis. Therefore, we hypothesized that …
[HTML][HTML] IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
CJ Greenbaum, E Serti, K Lambert, LJ Weiner… - JCI insight, 2021 - ncbi.nlm.nih.gov
Background IL-6 receptor (IL-6R) signaling drives development of T cell populations
important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with …
important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with …
Regulatory T cell therapy for type 1 diabetes: May the force be with you
SE Gitelman, JA Bluestone - Journal of autoimmunity, 2016 - Elsevier
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of insulin producing
beta cells. Regulatory T cells (Tregs) have been shown to be defective in this setting …
beta cells. Regulatory T cells (Tregs) have been shown to be defective in this setting …
Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance
M Battaglia, A Stabilini, E Draghici, S Gregori… - Diabetes, 2006 - Am Diabetes Assoc
Islet transplantation is a cure for type 1 diabetes, but its potential is limited by the need for
constant immunosuppression. One solution to this problem is the induction of transplantation …
constant immunosuppression. One solution to this problem is the induction of transplantation …
IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells
Regulatory T cells (T reg cells) play a major role in controlling the pathogenic autoimmune
process in type 1 diabetes (T1D). Interleukin 2 (IL-2), a cytokine which promotes T reg cell …
process in type 1 diabetes (T1D). Interleukin 2 (IL-2), a cytokine which promotes T reg cell …
mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
M Fraenkel, M Ketzinel-Gilad, Y Ariav, O Pappo… - Diabetes, 2008 - Am Diabetes Assoc
OBJECTIVE—Mammalian target of rapamycin (mTOR) and its downstream target S6 kinase
1 (S6K1) mediate nutrient-induced insulin resistance by downregulating insulin receptor …
1 (S6K1) mediate nutrient-induced insulin resistance by downregulating insulin receptor …